Dr. Chase S. Hall, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 374
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
KS license 04-41082 · MO license 2014009022
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- Stormont Vail Hospital Topeka, KS
- Lmh Lawrence, KS
- Ascension Via Christi Hospital Manhattan, Inc Manhattan, KS
Medical groups
- Kansas University Physicians Inc (1,849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 374
- Services billed
- 842
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 120 | 117 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 113 | 70 |
| Test to examine how well the lungs exchange gases | 109 | 109 |
| Test to determine lung volumes using sensors | 100 | 99 |
| Established patient office or other outpatient visit, 30-39 minutes | 82 | 63 |
| Critical care, first 30-74 minutes | 53 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 38 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 26 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | 26 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 145 |
| Mycophenolate Mofetil Other prescribers in Kansas City, KS | 52 |
| Prednisone Other prescribers in Kansas City, KS | 47 |
| Pirfenidone | 37 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Kansas City, KS | 30 |
| Methotrexate (methotrexate sodium) Other prescribers in Kansas City, KS | 14 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Kansas City, KS | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 35 payments worth $138,659 in total to this clinician.
| Polarean, Inc. | $115,787 |
|---|---|
| GlaxoSmithKline, LLC. | $11,700 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,865 |
| United Therapeutics Corporation | $308 |
| Consulting Fee | $126,700 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $10,050 |
| Food and Beverage | $1,039 |
| Travel and Lodging | $870 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Polarean, Inc. Jan 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Feb 3, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Mar 4, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Apr 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. May 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Jun 3, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Jul 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Aug 4, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Sep 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Oct 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Polarean, Inc. Dec 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Nov 4, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,290 |
| Polarean, Inc. Oct 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Sep 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Aug 4, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Jul 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Jun 3, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| GlaxoSmithKline, LLC. Jun 3, 2025 | Consulting Fee | $650 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,380 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,380 |
| Polarean, Inc. May 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 29, 2025 | Travel and Lodging travel to Bismarck, ND · in-kind | $199 |
| Polarean, Inc. Apr 1, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Mar 4, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Feb 3, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
| Polarean, Inc. Jan 29, 2025 | Travel and Lodging XENOVIEW · Respiratory · travel to Miami, FL · in-kind | $363 |
| GlaxoSmithKline, LLC. Jan 16, 2025 | Consulting Fee SHINGRIX · VACCINES | $7,800 |
| GlaxoSmithKline, LLC. Jan 16, 2025 | Consulting Fee | $3,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 15, 2025 | Travel and Lodging travel to Tulsa, OK · in-kind | $308 |
| Polarean, Inc. Jan 2, 2025 | Consulting Fee XENOVIEW · Respiratory | $9,583 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.